<DOC>
	<DOC>NCT01506947</DOC>
	<brief_summary>This study will be a prospective open label, non-randomised, single-arm, pilot clinical study evaluating the Effect of PTH Lowering on erythropoietin consumption in calcitriol resistant patients with stage 5 chronic kidney disease.</brief_summary>
	<brief_title>A Prospective Open-Label, Non-randomised, Single-arm, Pilot Clinical Study Evaluating the Effect of PTH Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>A subject will only be included if all the following entry criteria are met: Patients &gt;=18 years of age Stage 5 CKD patients receiving hemodialysis and with moderate to severe secondary hyperparathyroidism (SHPT) receiving hemodialysis Patients with anemia receiving EPO therapy with iron repletion; Transferrin saturation (TSAT) &gt; 20% and Ferritin levels &gt; 200 ng/mL and requiring treatment with erythropoietin (EPO) Patients with Vitamin B levels &gt; LLN and Folic acid levels &gt; LLN SATPatients with Vitamin B levels &gt; LLN and Folic acid levels &gt; LLN Patients treated only with intravenous calcitriol for at least 6 months Patients with serum iPTH level &gt; 500 pg/mL Patients with Ca . PO4 product &lt; 65 mg2/dL2 Patients willing to sign "written informed consents" before participating in any the study related activity. Patients with Ca levels &lt;6.5 mg/dL and P levels &lt;11.2 mg/dL A subject will be excluded from the study if he/she meets any of the following criteria: Patients who have known hypersensitivity and/or toxicity to vitamin D metabolites and/or to paricalcitol and/or to other product ingredients. Patients who have participated in a clinical study within the last month. Patients whose previous concomitant medication and laboratory data for 6 months prior to the baseline visit are not available. Patients with known contraindication to selective Vitamin D receptor activators (VDRAs) according to the SmPC. Pregnancy, Female patients pregnant, breastfeeding or planning a pregnancy within next 6 months after enrollment. Sexually active female patients not accepting appropriate contraceptive methods during the course of the study will also be excluded. Hypertensive and diabetic patients who are not on an optimal and steady medication regimen for more than 30 days. Patients with microcytic (MCV &lt; 80 fL) and macrocytic (MCV&gt; 100 fL) anemia at screening baseline that may be caused by diseases such as Micros Fe Deficiency, Thalassemias, Anemia of Chronic Disease, Copper Deficiency, Zn poisoning, Sideroblastic Anemia, Macrosethanol abuse, myelodysplastic syndromes, acute myeloid leukemias, reticulocytosis, drug induced anemia, liver disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Secondary hyperparathyroidism,</keyword>
	<keyword>Chronic kidney disease</keyword>
</DOC>